Literature DB >> 27554049

Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy.

Toru Kubo1, Yuri Ochi2, Yuichi Baba2, Takayoshi Hirota2, Katsutoshi Tanioka2, Naohito Yamasaki2, Makoto Yoshimitsu3, Koji Higuchi3, Toshihiro Takenaka3, Kimiko Nakajima4, Tadayasu Togawa5, Takahiro Tsukimura5, Shigetoshi Sano4, Chuwa Tei3, Hitoshi Sakuraba6, Hiroaki Kitaoka2.   

Abstract

BACKGROUND: The prevalence of Fabry disease (FD) in Japanese patients presenting with unexplained left ventricular hypertrophy (LVH) has remained unclear.
METHODS: We measured plasma α-galactosidase A activity in 177 men with a diagnosis of hypertrophic cardiomyopathy (HCM) (maximum LV wall thickness ≥15mm).
RESULTS: Two patients (1.1%) showed very low α-galactosidase A activity [0.0 and 0.3nmol/hr/ml (normal range: 3.6-17.6nmol/hr/ml)], and a clinical diagnosis of cardiac variant of FD was finally made. One patient was a 55-year-old man who came to our hospital because of abnormal results of electrocardiography and showed concentric LVH in echocardiography. A missense mutation, R112L, was identified. The other was a 74-year-old man who had been diagnosed with HCM at the age of 60 years in another hospital and was referred for evaluation of repeated hospitalization for heart failure. Although echocardiography revealed asymmetric septal hypertrophy (ASH) with interventricular septal wall thickness of 16mm and posterior wall thickness of 11mm and reduced LV ejection fraction with hypokinetic posterior wall motion, his echocardiographic findings at the initial diagnosis of HCM were not ASH but concentric LVH with normal LV systolic function. A splicing mutation, IVS4+919G>A, was identified.
CONCLUSIONS: The prevalence of FD in Japanese male patients with a clinical diagnosis of HCM was found to be 1.1%. These patients showed late onset and concentric LVH at initial presentation.
Copyright © 2016 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Fabry disease; Hypertrophic cardiomyopathy; Prevalence

Mesh:

Substances:

Year:  2016        PMID: 27554049     DOI: 10.1016/j.jjcc.2016.05.014

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  11 in total

1.  Low frequency of Fabry disease in patients with common heart disease.

Authors:  Raphael Schiffmann; Caren Swift; Nathan McNeill; Elfrida R Benjamin; Jeffrey P Castelli; Jay Barth; Lawrence Sweetman; Xuan Wang; Xiaoyang Wu
Journal:  Genet Med       Date:  2017-10-26       Impact factor: 8.864

2.  Importance of Echocardiography and Clinical "Red Flags" in Guiding Genetic Screening for Fabry Disease.

Authors:  Rodolfo Citro; Costantina Prota; Donatella Ferraioli; Giuseppe Iuliano; Michele Bellino; Ilaria Radano; Angelo Silverio; Serena Migliarino; Maria Vincenza Polito; Artemisia Ruggiero; Rosa Napoletano; Vincenzo Bellizzi; Michele Ciccarelli; Gennaro Galasso; Carmine Vecchione
Journal:  Front Cardiovasc Med       Date:  2022-04-25

3.  A prospective, observational study of patients with uncommon distal symmetric painful small-fiber neuropathy.

Authors:  Jung-Lung Hsu; Ming-Feng Liao; Hui-Ching Hsu; Yi-Ching Weng; Ai-Lun Lo; Kuo-Hsuan Chang; Hong-Shiu Chang; Hung-Chou Kuo; Chin-Chang Huang; Long-Sun Ro
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

Review 4.  Fabry disease and its cardiac involvement.

Authors:  Toru Kubo
Journal:  J Gen Fam Med       Date:  2017-05-08

5.  Fabry Disease with Pacemaker Implantation as the Initial Event.

Authors:  Yuji Kato; Ayako Ishikawa; Satoshi Aoki; Hiroyuki Sato; Yoshie Ojima; Saeko Kagaya; Tasuku Nagasawa
Journal:  Intern Med       Date:  2019-06-27       Impact factor: 1.271

Review 6.  Renal Manifestations of Fabry Disease: A Narrative Review.

Authors:  Cassiano Augusto Braga Silva; José A Moura-Neto; Marlene Antônia Dos Reis; Osvaldo Merege Vieira Neto; Fellype Carvalho Barreto
Journal:  Can J Kidney Health Dis       Date:  2021-01-19

7.  High Prevalence of Late-Onset Fabry Cardiomyopathy in a Cohort of 499 Non-Selective Patients with Left Ventricular Hypertrophy: The Asian Fabry Cardiomyopathy High-Risk Screening Study (ASIAN-FAME).

Authors:  Yiting Fan; Tsz-Ngai Chan; Josie T Y Chow; Kevin K H Kam; Wai-Kin Chi; Joseph Y S Chan; Erik Fung; Mabel M P Tong; Jeffery K T Wong; Paul C L Choi; David K H Chan; Bun Sheng; Alex Pui-Wai Lee
Journal:  J Clin Med       Date:  2021-05-17       Impact factor: 4.241

8.  Fabry disease in a Japanese population-molecular and biochemical characteristics.

Authors:  Hitoshi Sakuraba; Takahiro Tsukimura; Tadayasu Togawa; Toshie Tanaka; Tomoko Ohtsuka; Atsuko Sato; Tomoko Shiga; Seiji Saito; Kazuki Ohno
Journal:  Mol Genet Metab Rep       Date:  2018-10-26

Review 9.  Anderson-Fabry disease in heart failure.

Authors:  M M Akhtar; P M Elliott
Journal:  Biophys Rev       Date:  2018-06-16

10.  Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy.

Authors:  Chandu Sadasivan; Josie T Y Chow; Bun Sheng; David K H Chan; Yiting Fan; Paul C L Choi; Jeffrey K T Wong; Mabel M B Tong; Tsz-Ngai Chan; Erik Fung; Kevin K H Kam; Joseph Y S Chan; Wai-Kin Chi; D Ian Paterson; Manohara Senaratne; Neil Brass; Gavin Y Oudit; Alex P W Lee
Journal:  PLoS One       Date:  2020-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.